Découvrez nos professeurs et professeures!
Francesca Cicchetti
Professeure titulaire
Contribution à la recherche
Axe de recherche de l'Université Laval :
Santé et bien-être durables
Thématiques de recherche de la Faculté de médecine :
Neurosciences et santé mentale
Médecine régénératrice et médecine moléculaire
Domaines et intérêts de recherche du (de la) professeur(e) :
Neurosciences, santé mentale et toxicomanies
- Maladies neurodégénératives
- Chorée de Huntington
- Maladie de Parkinson
Projets de recherche
- Redefining PD pathophysiology mechanisms in the context of heterogeneous substantia nigra neuron subtypes - Michael J. Fox Foundation for Parkinson's Research - ASAP Collaborative Research Network, Northwestern University, co-chercheur - 2024-11-01 au 2026-10-31
- Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2020-04-01 au 2025-03-31
- Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-12-20 au 2024-12-19
- Premier biomarqueur sanguin de la maladie de Parkinson : de la validation à la commercialisation - Fondation du CHU de Québec, Synucure Thérapeutique inc., Ministère de l'Économie et de l'Innovation - Projets de maturation technologique PSO – volet 2d, chercheur principal - 2022-09-14 au 2024-09-13
- Redefining PD pathophysiology mechanisms in the context of teterogeneous substantia nigra neuron subtypes - Northwestern University - Target Advancement Program, chercheur principal - 2021-09-01 au 2024-08-31
- Crosstalk at the blood-brain barrier: new insights into Parkinson's disease - National Parkinson Foundation, chercheur principal - 2022-06-30 au 2024-06-30
- Untangling tau contribution to cognitive impairments in Huntington’s disease. - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2019-04-01 au 2024-03-31
- Les effets de la cystéamine chez les patients souffrant de la maladie de Huntington : Analyse des données cliniques - CHU de Québec – Université Laval – CHUL - Développement de la recherche (RFI), chercheur principal - 2023-01-01 au 2023-12-31
- Targeting the neurovascular unit to prevent disease dissemination and progression - Michael J. Fox Foundation for Parkinson's Research - Target Advancement Program, chercheur principal - 2021-01-01 au 2022-12-31
- Interrogating induced neuronal cells from Huntington’s disease patients to better understand cognitive impairments - Huntington's Disease Society of America, chercheur principal - 2019-11-01 au 2021-11-01
Publications
- Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain., , Experimental neurology, 2002, 10.1006/exnr.2002.8007
- Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases., , The Journal of experimental medicine, 2020, 10.1084/jem.20191430
- Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104530
- Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress., , Neurotoxicity research, 2004, 10.1007/bf03033216
- MyD88 deficiency results in both cognitive and motor impairments in mice., , Brain, behavior, and immunity, 2012, 10.1016/j.bbi.2012.02.007
- Striatal neurones displaying substance P (NK1) receptor immunoreactivity in human and non-human primates., , Neuroreport, 1995, 10.1097/00001756-199503270-00004
- The role of tau in the pathological process and clinical expression of Huntington's disease., , Brain : a journal of neurology, 2015, 10.1093/brain/awv107
- Differential expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits by calretinin-immunoreactive neurons in the human striatum., , Neuroscience, 1999, 10.1016/s0306-4522(99)00110-4
- Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease., , Human molecular genetics, 2014, 10.1093/hmg/ddu456
- Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration., , Proceedings of the National Academy of Sciences of the United States of America, 2009, 10.1073/pnas.0904239106
- Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology., , Proceedings of the National Academy of Sciences of the United States of America, 2000, 10.1073/pnas.97.25.13877
- Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons., , Proceedings of the National Academy of Sciences of the United States of America, 2016, 10.1073/pnas.1520387113
- Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease., , Brain research. Brain research reviews, 2000, 10.1016/s0165-0173(00)00039-4
- Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model., , Progress in neuro-psychopharmacology & biological psychiatry, 2009, 10.1016/j.pnpbp.2009.07.018
- A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in ParkinsonAU disease: PleasenotethatParkinsonsdiseasehasbeen, Oueslati, A., Saghatelyan, A., Fon, E.A., Cicchetti, F., Lévesque, M., Soulet, D., Tremblay, M.-E., Vallières, L., Durcan, T.M., Jeong, J.-W., Qazi, R., Cid-Pellitero, E.D., Luo, W., Tavassoly, O., St-Pierre, M.-K., Lamontagne-Proulx, J., Salesse, C., Dahmene, M., Dubois, M., Alpaugh, M., Turmel, R., Idi, W., Teixeira, M., Rodriguez-Aller, R., Malvaut, S., Sheta, R., Bérard, M., PLoS Biology, 2022, 10.1371/journal.pbio.3001578
- Current understanding of the glial response to disorders of the aging CNS., , Frontiers in pharmacology, 2012, 10.3389/fphar.2012.00095
- Mutant huntingtin protein expression and blood-spinal cord barrier dysfunction in huntington disease., , Annals of neurology, 2017, 10.1002/ana.25107
- Optogenetic-Mediated Spatiotemporal Control of α-Synuclein Aggregation Disrupts Nigrostriatal Transmission and Precipitates Neurodegeneration, Oueslati, A., Saghatelyan, A., Fon, E.A., Cicchetti, F., Jeong, J.-W., Lévesque, M., Soulet, D., Tavassoly, O., Qazi, R., Lamontagne-Proulx, J., Profes, M.S., Salesse, C., Dahmene, M., Dubois, M., Alpaugh, M.J., Turmel, R., Malvaut, S., Sheta, R., Bérard, M., SSRN, 2019, 10.2139/ssrn.3416893
- The effects of cysteamine in a mouse model of levodopa-induced dyskinesias., , Neuroscience letters, 2017, 10.1016/j.neulet.2017.10.062
- Impact of DHA intake in a mouse model of synucleinopathy., , Experimental neurology, 2017, 10.1016/j.expneurol.2017.12.002
- The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice., , Brain research, 2019, 10.1016/j.brainres.2019.01.016
- Targeting cerebrovascular impairments in Huntington's disease: a novel treatment perspective., , Neurodegenerative disease management, 2015, 10.2217/nmt.15.41
- Can we prevent Parkinson's disease with n-3 polyunsaturated fatty acids?, Cicchetti, F., Calon, F., Future Lipidology, 2008, 10.2217/17460875.3.2.133
- Targeting Tau to Treat Clinical Features of Huntington's Disease., , Frontiers in neurology, 2020, 10.3389/fneur.2020.580732
- Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease., , Neurobiology of disease, 2018, 10.1016/j.nbd.2018.11.002
- Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu047
- Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu103
- Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications., , Brain : a journal of neurology, 2011, 10.1093/brain/awq328
- The role of immunity in Huntington's disease., , Molecular psychiatry, 2011, 10.1038/mp.2011.28
- GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions., , Cell death & disease, 2016, 10.1038/cddis.2016.104
- The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity., , Brain, behavior, and immunity, 2011, 10.1016/j.bbi.2011.02.017
- Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions., , Journal of neurochemistry, 2009, 10.1111/j.1471-4159.2009.06072.x
- Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience., , Parkinsonism & related disorders, 2021, 10.1016/j.parkreldis.2021.08.018
- Outcome of cell suspension allografts in a patient with Huntington's disease., , Annals of neurology, 2018, 10.1002/ana.25354
- Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104941
- The troubling story of blood-driven dementias., , Molecular psychiatry, 2019, 10.1038/s41380-018-0225-z
- The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration., , Journal of neuroinflammation, 2011, 10.1186/1742-2094-8-137
- The current model of basal ganglia organization under scrutiny., , Movement disorders : official journal of the Movement Disorder Society, 1998, 10.1002/mds.870130202
- Platelet-derived extracellular vesicles in Huntington's disease., , Journal of neurology, 2018, 10.1007/s00415-018-9022-5
- Technical factors that influence neural transplant safety in Huntington's disease., , Experimental neurology, 2010, 10.1016/j.expneurol.2010.08.031
- Calretinin gene expression in the human thalamus., , Brain research. Molecular brain research, 1998, 10.1016/s0169-328x(97)00314-8
- Healthy blood, healthy brain: a window into understanding and treating neurodegenerative diseases, Francesca Cicchetti, Aurélie de Rus Jacquet, Thyago R. Cardim-Pires, Journal of Neurology, 2024, 10.1007/s00415-024-12337-w
- Calcium-binding proteins in primate basal ganglia., , Neuroscience research, 1996, 10.1016/0168-0102(96)01065-6
- Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?, , Trends in pharmacological sciences, 2009, 10.1016/j.tips.2009.06.005
- Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging., , The European journal of neuroscience, 2002, 10.1046/j.1460-9568.2002.01938.x
- Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases., , Journal of neurochemistry, 2010, 10.1111/j.1471-4159.2010.06874.x
- Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance., , Molecular psychiatry, 2021, 10.1038/s41380-021-01350-4
- Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats., , Neurobiology of disease, 2005, 10.1016/j.nbd.2005.03.018
- Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease., , FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, 10.1096/fj.07-9677com
- Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability., , Brain : a journal of neurology, 2013, 10.1093/brain/aws359
- Antibody-based therapies for Huntington's disease: current status and future directions., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104569
- The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence., , Neuropathology and applied neurobiology, 2014, 10.1111/nan.12104
- An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity., , Cell death & disease, 2012, 10.1038/cddis.2012.121
- Passive immunization against phosphorylated tau improves features of Huntington's disease pathology, Francesca Cicchetti, Emmanuel Planel, Peter Davies, Martine Saint-Pierre, Hélèna L. Denis, Eva Lepinay, Aurelie de Rus Jacquet, Maria Masnata, Melanie Alpaugh, Molecular Therapy, 2022, 10.1016/j.ymthe.2022.01.020
- Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders., , Journal of experimental neuroscience, 2018, 10.1177/1179069518772380
- Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene., , Brain research, 1999, 10.1016/s0006-8993(98)01312-2
- The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository., , Journal of Parkinson's disease, 2020, 10.3233/jpd-191775
- Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling., , Cell reports, 2014, 10.1016/j.celrep.2014.10.008
- Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor., , Progress in neuro-psychopharmacology & biological psychiatry, 2009, 10.1016/j.pnpbp.2009.11.005
- The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?, , Frontiers in pharmacology, 2014, 10.3389/fphar.2014.00139
- The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications., , Frontiers in neuroscience, 2017, 10.3389/fnins.2017.00647
- Neuroprotective effects of cystamine in aged parkinsonian mice., , Neurobiology of aging, 2006, 10.1016/j.neurobiolaging.2005.04.004
- Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.105042
- Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model., , NeuroImage, 2003, 10.1016/s1053-8119(03)00348-3
- Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease., , Cell transplantation, 2013, 10.3727/096368913x668636
- Dual-modality in vivo monitoring of subventricular zone stem cell migration and metabolism., , Contrast media & molecular imaging, 2007, 10.1002/cmmi.138
- Neuroanatomy and neuroscience at a glance, , Wiley-Blackwell, 2012
- Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease., , Journal of the neurological sciences, 2005, 10.1016/j.jns.2004.12.011
- Is Huntington's disease a tauopathy?, , Brain : a journal of neurology, 2016, 10.1093/brain/aww021
- Prompting endogenous repair of brain injury: science fiction or reality?, Cicchetti, F., de Rus Jacquet, A., Molecular Neurodegeneration, 2022, 10.1186/s13024-022-00539-7
- The different effects of LPS and poly I:C prenatal immune challenges on the behavior, development and inflammatory responses in pregnant mice and their offspring., , Brain, behavior, and immunity, 2013, 10.1016/j.bbi.2013.12.016
- Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders, Melanie Alpaugh, Francesca Cicchetti, Hélèna L. Denis, Aurélie de Rus Jacquet, Molecular Psychiatry, 2021, 10.1038/s41380-020-00999-7
- Inflammation and neurodegeneration: the story 'retolled'., , Trends in pharmacological sciences, 2012, 10.1016/j.tips.2012.07.002
- Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms., , Acta neuropathologica, 2019, 10.1007/s00401-019-01973-6
- Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease., , Neurobiology of disease, 2015, 10.1016/j.nbd.2015.07.012
- Disease-like degeneration in neural transplants, Cicchetti, F., Freeman, T.B., Proceedings of the National Academy of Sciences of the United States of America, 2009, 10.1073/pnas.0908449106
- A brief history of antibody-based therapy., , Neurobiology of disease, 2019, 10.1016/j.nbd.2019.104504
- Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007, 10.2967/jnumed.106.037796
- Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104943
- Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system., , The Journal of nutritional biochemistry, 2015, 10.1016/j.jnutbio.2015.11.014
- Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases., , Progress in neuro-psychopharmacology & biological psychiatry, 2010, 10.1016/j.pnpbp.2010.11.023
- Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease., , Brain : a journal of neurology, 2017, 10.1093/brain/awx255
- Anatomy and physiology of the basal ganglia,Anatomie et physiopathologie des ganglions de la base, Cicchetti, F., Parent, A., Neurochirurgie, 1997
- Are immunotherapies for Huntington's disease a realistic option?, , Molecular psychiatry, 2018, 10.1038/s41380-018-0021-9
- Chemical phenotype of calretinin interneurons in the human striatum., , Synapse (New York, N.Y.), 1998, 10.1002/(sici)1098-2396(199811)30:3<284::aid-syn6>3.0.co;2-7
- Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease., , Journal of lipid research, 2010, 10.1194/jlr.m011692
- Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells., , Parkinsonism & related disorders, 2001, 10.1016/s1353-8020(00)00059-6
- Neurodegenerative disorders: the Glia way forward., , Frontiers in pharmacology, 2014, 10.3389/fphar.2014.00157
- A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice., , The Journal of physiology, 2015, 10.1113/jphysiol.2014.287243
- Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates., , Neurobiology of disease, 2020, 10.1016/j.nbd.2020.104951
- A novel wireless brain stimulation device for long-term use in freely moving mice., , Scientific reports, 2019, 10.1038/s41598-019-42910-7
- Human-to-mouse prion-like propagation of mutant huntingtin protein., , Acta neuropathologica, 2016, 10.1007/s00401-016-1582-9
- Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology., , Molecular psychiatry, 2020, 10.1038/s41380-020-0787-4
- Viability of the rotenone model in question, , Trends in Pharmacological Sciences, 2010, 10.1016/j.tips.2009.12.008
- The morphological and molecular changes of brain cells exposed to direct current electric field stimulation., , The international journal of neuropsychopharmacology, 2014, 10.1093/ijnp/pyu090
- Calcium-binding proteins in primate basal ganglia, Cicchetti, F., Côté, P.-Y., Fortin, M., Parent, A., Neuroscience Research, 1996, 10.1016/S0168-0102(96)01065-6
- Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology., , Annals of neurology, 2015, 10.1002/ana.24406
- Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology., , Journal of neuroinflammation, 2020, 10.1186/s12974-020-01782-9
- [Anatomy and physiopathology of the basal ganglia], , Neuro-Chirurgie, 1997
- Mutant huntingtin is present in neuronal grafts in Huntington disease patients., , Annals of neurology, 2014, 10.1002/ana.24174
- Huntington's disease: lessons from prion disorders., , Journal of neurology, 2021, 10.1007/s00415-021-10418-8
- Impact of ω-3 fatty acids in Parkinson's disease., , Ageing research reviews, 2011, 10.1016/j.arr.2011.03.001
- Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders., , Molecular psychiatry, 2021, 10.1038/s41380-021-01055-8
- Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions., , Glia, 2011, 10.1002/glia.21086
- Rotenone induces non-specific central nervous system and systemic toxicity., , FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, 10.1096/fj.03-0677fje
- Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?, , Acta neuropathologica, 2015, 10.1007/s00401-015-1518-9
- 3-Nitropropionic acid-induced neurotoxicity--assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy., , Journal of neurochemistry, 2004, 10.1111/j.1471-4159.2004.02408.x
- High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice., , Neurobiology of disease, 2011, 10.1016/j.nbd.2011.09.009
- Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease., , Journal of neuroinflammation, 2012, 10.1186/1742-2094-9-234
- Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins., , Cell reports, 2021, 10.1016/j.celrep.2021.109975
- microRNA-132/212 deficiency enhances Aβ production and senile plaque deposition in Alzheimer's disease triple transgenic mice., , Scientific reports, 2016, 10.1038/srep30953
- Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons., , Movement disorders : official journal of the Movement Disorder Society, 1996, 10.1002/mds.870110605
- Immune parameters relevant to neural xenograft survival in the primate brain., , Xenotransplantation, 2003, 10.1034/j.1399-3089.2003.01130.x
- Tau: a biomarker of Huntington’s disease, Francesca Cicchetti, Eva Lepinay, Molecular Psychiatry, 2023, 10.1038/s41380-023-02230-9
- Omega-3 fatty acid in Parkinson disease, Cicchetti, F., Calon, F., Agro Food Industry Hi-Tech, 2009
- Pesticides and Parkinson’s Disease, , Pesticides - The Impacts of Pesticides Exposure, 2011
- Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum., , Neuroscience, 2001, 10.1016/s0306-4522(01)00098-7
- Single-axon labeling study of the nigrostriatal dopaminergic system: Possible clues to parkinson's disease pathology, Cicchetti, F., Brain Pathology, 1998
- Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease., , Brain research, 1996, 10.1016/0006-8993(96)00307-1
- Calretinin-immunoreactive neurons in the human striatum., , Brain research, 1995, 10.1016/0006-8993(95)00124-9
- Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat., , Experimental neurology, 2001, 10.1006/exnr.2001.7823
- Platelet abnormalities in Huntington's disease., , Journal of neurology, neurosurgery, and psychiatry, 2018, 10.1136/jnnp-2018-318854
- Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats., , Journal of neurochemistry, 2006, 10.1111/j.1471-4159.2006.03923.x
- Correction: Shedding a new light on Huntington’s disease: how blood can both propagate and ameliorate disease pathology (Molecular Psychiatry, (2021), 26, 9, (5441-5463), 10.1038/s41380-020-0787-4), Cicchetti, F., Lacroix, S., Wanker, E.E., Ast, A., Gould, P.V., Oueslati, A., Truant, R., Isenring, P., Garneau, A.P., Bazenet, C., Herrmann, F., Lévesque, S.A., Denis, H.L., Masnata, M., Saint-Pierre, M., Sciacca, G., Alpaugh, M., Rieux, M., Molecular Psychiatry, 2021, 10.1038/s41380-020-0850-1
Contribution à l'enseignement aux cycles supérieurs
Étudiant(e)s dirigé(e)s*
Depuis 2009- Christine Trabolsi - Doctorat - En cours
- Eva Lepinay - Doctorat - En cours
- Sonia Catalina Cerquera Cleves - Doctorat - En cours
- Flavia Natale Alves Martins Borba - Doctorat - En cours
- Thyago Cardim Pires - Post-doctorat - En cours
- Karl-Indel Gué - Maîtrise avec mémoire - 2012/01
- Giulia Cisbani - Doctorat - 2014/09
- Simon Pelletier - Maîtrise avec mémoire - 2015/01
- Marie Rieux - Maîtrise avec mémoire - 2017/01
- Katherine Coulombe - Maîtrise avec mémoire - 2017/09
- Marilyn Dubois - Maîtrise avec mémoire - 2018/01
- Jérôme Lamontagne-Proulx - Maîtrise avec mémoire - 2018/01
- Sara Rainone - Doctorat - 2018/09
- Alexander Maxan - Maîtrise avec mémoire - 2019/01
- Florian Lauruol - Maîtrise avec mémoire - 2019/05
- Josiane Dufour - Maîtrise avec mémoire - 2020/05
- Maria Masnata - Doctorat - 2020/09
- Héléna Denis - Maîtrise avec mémoire - 2021/01
- Alberto Siddu - Doctorat - 2021/01
- Giacomo Sciacca - Doctorat - 2021/09
Encadrement d'étudiant(e)s
Direction de recherche dans les domaines suivants :
- Médecine moléculaire
- Neurobiologie — Neurosciences
En savoir plus sur les programmes
Disponibilité d'encadrement d'étudiant(e)s
Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.
Envoyer un courriel